NEW YORK (GenomeWeb) – T2 Biosystems has launched its initial public offering of 5.2 million shares of common stock at a price of $11 per share, bringing in gross proceeds of $57.2 million.

The Lexington, Mass.-based molecular diagnostics firm said that it has granted the underwriters a 30-day option to purchase an additional 780,000 share at the offering price. It expects to begin trading on the Nasdaq Global market today under ticker symbol "TTOO."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.